Drug Repurposing Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Drug repurposing, also known as drug repositioning, refers to the process of discovering new therapeutic applications for existing, already-approved medications. This approach significantly reduces the time and cost associated with bringing a new drug to market, as safety profiles and pharmacokinetics are already well-characterized. The market encompasses services and technologies across therapeutic areas including oncology, central nervous system disorders, and infectious diseases.

• •The market was valued at approximately $32.6 billion in 2024 and is projected to reach roughly $36.13 billion in 2025
• •Growth is expected at approximately 3.96% annually through the mid-2030s
• •Includes both software/AI platforms and pharmaceutical company-led initiatives

Escalating drug development costs and lengthy timelines for novel therapeutics make repurposing an increasingly attractive strategy for pharmaceutical companies and investors. Advances in artificial intelligence, computational biology, and real-world data analytics have dramatically improved the ability to identify viable repurposing candidates across diverse drug libraries. Additionally, the urgent need to address unmet medical needs in areas such as oncology, neurodegeneration, and rare diseases continues to drive investment and research in this space.

• •Average cost of developing a new drug exceeds $2 billion, making repurposing a cost-effective alternative
• •AI and machine learning platforms now enable rapid screening of thousands of compounds for new therapeutic indications
• •Regulatory pathways such as the FDA's 505(b)(2) and orphan drug designations support and incentivize repurposing efforts

The market is segmented primarily by therapeutic area, with oncology representing one of the largest and most active segments due to the complexity of cancer biology and the need for novel treatment combinations. Central nervous system disorders, including Alzheimer's and Parkinson's disease, constitute another major segment given the high failure rates of de novo drug development in these areas. Geographically, North America holds the largest market share, followed by Europe and the Asia-Pacific region, with emerging markets showing increasing adoption of repurposing strategies.

• •Key therapeutic segments include oncology, CNS disorders, infectious diseases, and cardiovascular conditions
• •North America leads the market, supported by advanced research infrastructure and favorable regulatory frameworks
• •Asia-Pacific is expected to see accelerated growth driven by expanding pharmaceutical manufacturing capabilities and increasing R&D investment

What are the recent trends and outlook?

The convergence of artificial intelligence, big data, and multi-omics is expected to accelerate the identification of novel repurposing candidates and improve success rates in clinical development. Increased emphasis on personalized medicine and combination therapies is creating new opportunities for repositioned drugs, particularly in oncology and immunology. Over the coming decade, the market is likely to see greater collaboration between technology companies, academic institutions, and pharmaceutical manufacturers, with a continued shift toward platform-based approaches that can systematically evaluate large compound libraries.

• •AI-driven platforms are projected to reduce the average time to identify repurposing candidates from years to months
• •Combination therapies involving repurposed drugs and novel agents are an emerging focus in oncology and immunology
• •Market projections suggest the sector could approach $59 billion by 2034 if current growth trajectories hold